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Vaccinia Virus (Poxvirus family) is closely related to other viruses in the Orthopoxvirus 
genus, e.g. Variola Virus, Monkeypox and Cowpox [1], and can be used as a surrogate model 
of Orthopoxvirus infection in antiviral studies at BSL2. Vaccinia WR is associated with 
Postvaccinial Encephalitis, a rare but severe complication of Smallpox vaccination with 
replicating viruses [2]. Encephalitis was regularly observed in Smallpox cases. 
 
In this project we have used fully replication competent Vaccinia Virus strain WR to test the 
antiviral activity of natural plant extracts prepared in the laboratory of Les Baillie, School of 
Pharmacy and Pharmaceutical Sciences in Cardiff. 
 
A luciferase-expressing vaccinia virus WR (v3- LUC240) was used to both investigate the 
capability of the substances to prevent the early stage of infection (virus entry; at 4 hours 
p.i.- reporter activity) and the later stage of infection (at 3 days p.i.- viability assay; at 5 days 
p.i.- plaque reduction assay). The extracts were screened at a single concentration; the 
activity and toxicity spectra of effective extracts were further characterized. The clinically 
approved drug Cidofovir (CDV) and the experimental autophagy inhibitor cf2642 were used 
as inhibition controls. 
 
Organotypic cell lines A549 (human alveolar epithelial cell; lung), HUH-7 (human hepatoma; 
liver), and DBTRG (human glioblastoma; brain) were used. From preliminary data, we have 
found that Taraxacum officinale (Dandelion) extract fraction 9 (BB4-D9) tested at 6.4ug/mL 
had an efficacy comparable to CDV at 10μ M in A549. Further subfractions of BB4-D9 are to 
be tested to identify the active component of Taraxacum officinale plant extract. 
 
